Regeneron
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Regeneron and other ETFs, options, and stocks.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
REGN News
Loading... Loading... On Thursday, Regeneron Pharmaceuticals Inc REGN reported first-quarter adjusted EPS of $9.55, down 5% Y/Y, missing the consensus of $10.1...
In this article: Regeneron stock jumped early Thursday, bolstered by strong sales of a high-dose version of its blockbuster eye disease treatment, Eylea....
Regeneron Pharmaceuticals, Inc. REGN delivered lower-than-expected first-quarter 2024 results due to declining sales of its lead drug, Eylea (aflibercept). The...
Analyst ratings
69%
of 29 ratingsMore REGN News
Revenue: Reported at $3.15 billion, a decrease of 1% year-over-year, falling short of estimates of $3.22 billion. Net Income: GAAP net income reached $722 mill...
It is hard to get excited after looking at Regeneron Pharmaceuticals' (NASDAQ:REGN) recent performance, when its stock has declined 6.8% over the past month. Bu...
Regeneron Pharmaceuticals (NASDAQ:REGN) traded lower in the premarket Thursday despite a newly announced $3B worth of share buybacks as the Eylea maker fell sho...
Regeneron stock fell slightly early Thursday after the biotech giant reported adjusted earnings of $9.55 per share on $3.15 billion in first-quarter sales. X...
(Adds details and background on Eylea in paragraphs 5 and 7, sales of other drugs in paragraphs 8 and 9) May 2 (Reuters) - U.S. drugmaker Regeneron Pharmaceuti...
Sanofi (NASDAQ:SNY) Q1 2024 Earnings Call Transcript April 25, 2024 Sanofi reports earnings inline with expectations. Reported EPS is $0.96 EPS, expectations w...
Loading... Loading... Benzinga's options scanner has just identified more than 16 option transactions on Regeneron Pharmaceuticals REGN, with a cumulative valu...
